Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- Icahn School of Medicine at Mount Sinai
- Principal investigator
- James Murrough
- Start date
- 2025-02-25
- End date
- 2028-03-01
- Registry ID
- NCT06592833
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.